Barinthus Biotherapeutics Statistics
Total Valuation
BRNS has a market cap or net worth of $24.92 million. The enterprise value is -$33.44 million.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BRNS has 40.85 million shares outstanding. The number of shares has increased by 3.00% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 40.85M |
| Shares Change (YoY) | +3.00% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 11.74% |
| Owned by Institutions (%) | 27.70% |
| Float | 27.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.35 |
| P/TBV Ratio | 0.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.77, with a Debt / Equity ratio of 0.15.
| Current Ratio | 7.77 |
| Quick Ratio | 7.16 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,138.59 |
Financial Efficiency
Return on equity (ROE) is -65.02% and return on invested capital (ROIC) is -31.88%.
| Return on Equity (ROE) | -65.02% |
| Return on Assets (ROA) | -28.08% |
| Return on Invested Capital (ROIC) | -31.88% |
| Return on Capital Employed (ROCE) | -65.87% |
| Weighted Average Cost of Capital (WACC) | 0.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.74M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -175,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.08% in the last 52 weeks. The beta is -0.60, so BRNS's price volatility has been lower than the market average.
| Beta (5Y) | -0.60 |
| 52-Week Price Change | -25.08% |
| 50-Day Moving Average | 0.60 |
| 200-Day Moving Average | 0.94 |
| Relative Strength Index (RSI) | 53.47 |
| Average Volume (20 Days) | 17,980 |
Short Selling Information
The latest short interest is 8,236, so 0.03% of the outstanding shares have been sold short.
| Short Interest | 8,236 |
| Short Previous Month | 10,469 |
| Short % of Shares Out | 0.03% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.24 |
Income Statement
| Revenue | n/a |
| Gross Profit | -133,000 |
| Operating Income | -58.07M |
| Pretax Income | -66.63M |
| Net Income | -66.43M |
| EBITDA | -55.22M |
| EBIT | -58.07M |
| Earnings Per Share (EPS) | -$1.64 |
Full Income StatementBalance Sheet
The company has $70.46 million in cash and $11.28 million in debt, giving a net cash position of $59.18 million or $1.45 per share.
| Cash & Cash Equivalents | 70.46M |
| Total Debt | 11.28M |
| Net Cash | 59.18M |
| Net Cash Per Share | $1.45 |
| Equity (Book Value) | 74.29M |
| Book Value Per Share | 1.82 |
| Working Capital | 67.77M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$47.98 million and capital expenditures -$37,000, giving a free cash flow of -$48.02 million.
| Operating Cash Flow | -47.98M |
| Capital Expenditures | -37,000 |
| Depreciation & Amortization | 2.85M |
| Net Borrowing | n/a |
| Free Cash Flow | -48.02M |
| FCF Per Share | -$1.18 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |